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(Requests for offprints should be addressed to E C degli Uberti; Email: dut@unife.it)AbstractElevatedcirculatingchromograninA (CgA) levelsare found inneuroendocrine tumors (NETs), but the
diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of
gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian
multicenter observational study has been performed. CgA was evaluated in 202 GEP NET patients
by IRMA and ELISA. The cutoffs for diagnosis and presence of metastases were identified by
receiver-operating characteristic (ROC)curve.We foundgoodcorrelationbetween IRMAandELISA.
The ROC analysis identified a cutoff of 53 ng/ml for IRMA and 16 U/l for ELISA as discriminating
between controls and patients with active disease (sensitivity 71.3 and 84%; specificity 71 and 85%
respectively). Metastases were present in 123 patients, having significantly higher CgA levels than
patients without metastases. ROC analysis identified a cutoff of 146 ng/ml for IRMA and 67.3 U/l for
ELISA as discriminating between patients with and without metastases (sensitivity 57 and 63.3%;
specificity 55.6 and 71.4% respectively). For pancreatic NETs positive and negative predictive
values were 84 and 78% respectively (90% specificity and 68% sensitivity). We found lower CgA
levels in patients with extensive metastatic spread than in those with liver metastases only. These
data assess the role of CgA evaluation in GEP NETs, and demonstrate that higher CgA levels
associate with metastatic disease, confirming that CgA levels can provide a helpful practical
biochemical marker for the clinical management of NETs, but with low sensitivity and specificity.Endocrine-Related Cancer (2007) 14 473–482Introduction
Chromogranin A (CgA) is an acidic glycoprotein
expressed in the secretory granules of most normal and
neoplastic neuroendocrine (NE) cell types, where it is
released together with peptide hormones and biogenic
amines (Taupenot et al. 2003). Elevated circulating CgA
levels have been demonstrated in serum or plasma of
patients with various NE tumors (NETs; Nobels et al.
1997, Guignat et al. 2001, Tomassetti et al. 2001).Endocrine-Related Cancer (2007) 14 473–482
1351–0088/07/014–473 q 2007 Society for Endocrinology Printed in GreatPrevious studies reported different ranges of sensitivity
and specificity for circulating CgA, according to
histological characteristics of the tumor and to disease
spread. These parameters have been demonstrated to
depend also on themethod used for serumorplasmaCgA
determination and on the threshold considered as
pathologic (Schu¨rmann et al. 1992, Stridsberg et al.
1995, Nobels et al. 1997, Baudin et al. 2001, Stivanello
et al. 2001, Tomassetti et al. 2001). In order to clarify thisBritain
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M C Zatelli et al.: CgA in neuroendocrine tumorsissue, an Italianmulticenter observational study has been
performed in a large series of gastroenteropancreatic
(GEP) NET patients and healthy controls to assess the
usefulness of CgA determination for the diagnosis of
sporadic GEPNETs and to establish the best cutoff value
for the diagnosis of GEP NETs using the method of the
receiver-operating characteristic (ROC) curve.Materials and methods
Subjects
The control group was composed of 129 healthy
individuals (61 males and 68 females; aged 44.2G8.4
years (meanGS.D.); range 22–59 years)without evidence
of NETs, malignancies, hypertension, renal or liver
failure, and not treated with proton pump inhibitors.
Overall, 273 patients with NETs were enrolled
between April 2003 and October 2004 in 40 different
Italian centers, participating to the CROMaNET study, a
multicenter observational study for the evaluation of
CgA as marker for diagnosis and follow-up of NET.
Among these subjects, 202 patients (109 males and 93
females; aged58.5G13.8years; range 14–84years)were
diagnosed from 1 to 120 months earlier (median 45
months) with GEP NET, pathologically proven by
histological and immunohistochemical diagnosis after
surgery or biopsy of primary tumor or metastases.
Exclusion criteria were kidney defect (plasma creati-
nineO120 mM/l; Canale & Bravo 1994), liver failure,
treatment with proton pump inhibitors, Parkinson’s
disease, pregnancy, or the presence of any other
malignancy.
The GEP NET group included 73 patients with
primitive NET site in the pancreas, 2 in the esophagus,
27 in the stomach, 7 in the duodenum, 71 in the ileum,
14 in the colon, and 8 in the rectum. Conventional
imaging (abdominal and thoracic CT and/or MRI), as
well as ultrasonography, endoscopy, echo-endoscopy,
and somatostatin receptor scintigraphy (Octreoscan)
were used for staging when appropriate. Among these
patients, 123 (60.9%) presented with metastases. The
extent of metastatic spread was defined as locally
advanced (when limited to regional lymph nodes), with
liver metastases (when only liver metastases were
evident) and with liver and extra-hepatic metastases
(when bone, lung, or brain metastases were demon-
strated). Patients were divided into four groups:
1) new diagnosis (ND, 81 patients): including
patients diagnosed at the centre for the first time
as having a GEP NET, with evidence of disease at
study entry;4742) relapse (RL, 27 patients): patients with evidence
of recurrent disease, not medically treated for at
least 6 months before study entry;
3) stable disease (SD, 49 patients): patients with
evidence of persistent disease, medically treated
for at least 6 months before study entry;
4) remission (RM, 45 patients): patients previously
treated (either surgically or medically) for a GEP
NET, with no evidence of disease at study entry.CgA determination
All samples were collected after an overnight fast, as
previously described (Leon et al. 2005), for plasma and
serum, both aliquoted and stored at K80 8C. Measure-
ment of serum CgA levels was performed between
February and July 2005, both locally and in two reference
laboratories, by a two-step IRMA (IRMA; CGA-RIA
CT, CIS-bio international-Shering, Gif-sur-Yvette,
France) in Venezia (ABO Association c/o Regional
Center for the Study of Biological Markers of Malig-
nancy,General RegionalHospital, Venezia, Italy) and by
ELISA (DAKO Cytomation, Glostrup, Denmark) in
Orbassano (Medical Oncology Unit, S. Luigi Hospital,
Orbassano, Torino, Italy). Bothmethodswere performed
according to themanufacturer’s instructions.All samples
were assayed in duplicate by the same technician.
The IRMA assay is based on two monoclonal
antibodies raised against the unprocessed central domain
(CgA145–245) of the human CgA, allowing sensitive
detection of total humanCgA.Recombinant humanCgA
was used as calibrator and the standard curve concen-
trations ranged from 22 to 1200 ng/ml, with a minimal
detectable level of 10 ng/ml. Inter-assay coefficients of
variation were 3.4 and 4.5% at 124.7 and 355.2 ng/ml
respectively. Intra-assay coefficients of variation were
5.1, 3.0, and 7.8% for the following ranges 15–25,
90–110, and 500–700 ng/ml respectively.
The ELISA assay is based on two polyclonal rabbit
antibodies directed towards a 23 kDa carboxyl-
terminal fragment of human CgA, therefore measuring
more human CgA fragments. The calibrators were
extracted from urine of patients with carcinoids and the
standard curve concentrations ranged from 5 to
650 U/l, with a minimal detectable level of 5 U/l.
Inter-assay coefficients of variation were 3.4, 3.9, and
6.8% at 11.5, 52.7, and 358 U/l respectively. Intra-
assay coefficients of variation were 4.5, 3.8, and 8.5%
for the following ranges 5–10, 15–25, and 250–450 U/l
respectively.www.endocrinology-journals.org
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Table 1 Basal chromogranin A levels in 129 healthy subjects
assessed by IRMA and ELISA
IRMA (ng/ml) ELISA (U/l)
No. 129 129
Mean 46.9 12.3
S.D. 31.2 10.1
Median 40.0 10.4
Range 17–269 5–106.5
Percentile
5th 21.0 6.2
25th 31.0 8.0
50th 40.0 10.4
75th 54.0 13.7
95th 86.0 19.3
Endocrine-Related Cancer (2007) 14 473–482Statistical analysis
CgA levels are reported as the meanGS.D., the median,
and the range for both IRMA and ELISA methods.
Comparisons of values from independent groups were
performed using the nonparametric test of Wilcoxon.
To measure the strength of association between pairs of
variables without specifying dependencies, Spearman
order correlations were run. A P!0.05 was considered
significant in all tests.
In order to identify a cutoff CgA value for both
IRMA and ELISA assays that could discriminate
between controls and patients, a ROC curve was
constructed using CgA levels from the 129 controls
and those from 81 ND patients with GEP NETs, which
were considered as having the disease at the moment of
blood sampling. In order to identify a cutoff CgA value
for both IRMA and ELISA assays that could
discriminate between patients without and with
metastases, a ROC curve was constructed using CgA
levels from 29 patients without metastases and those
from 79 metastatic patients belonging to the ND and
RL groups (108 patients), all considered as having the
disease at the moment of blood sampling.
ROC analysis was performed using a statistical
software package (SAS, version 8.2). The area under
the ROC curve (AUC) was calculated to describe the
capability of the marker to discriminate between patients
and controls. Sensitivity and specificity were calculated
for different cutoff values. The optimal value giving the
best compromise between sensitivity and specificity was
chosen to analyze the performance ofCgA assays inGEP
NET patients. Sensitivity and specificity were calculated
using the standard formulae (sensitivity %Ztrue
positive/true positiveCfalse negative and specificity
%Ztrue negative/true negativeCfalse positive). The
correction for the disease prevalence was adopted to
calculate positive predictive value (PPV) and negative
predictive value (NPV): PPV (%; probability that a
positive value corresponds to a true positive result)Z
sensitivity/sensitivityC(1Kspecificity)/prevalence of
disease and NPV (%; probability that a negative value
corresponds to true negative result)Zspecificity/specifi-
cityC(1Ksensitivity)!prevalence of disease.Results
CgA levels in healthy subjects and in GEP NET
patients
CgA levels, assessed by both IRMA and ELISA
methods, were highly variable and not normally
distributed among the 129 healthy subjects (Table 1)www.endocrinology-journals.organd in the 202 GEP NET patients (Table 2). The
analysis of collected data showed a good correlation
between IRMA and ELISA assays in measuring CgA
levels both in healthy subjects (rZ0.689; P!0.0001;
Fig. 1A) and in GEP NET patients (rZ0.848; P!
0.0001; Fig. 1B). In addition, a good correlation
between local and central laboratories in measuring
CgA levels both with IRMA (rZ0.846; P!0.0001;
Fig. 2A) and with ELISA assays (rZ0.873; P!
0.0001) was found (Fig. 2B).Diagnostic property of CgA
In order to identify a cutoff value that could distinguish
between healthy subjects and affected patients, we
performed a ROC analysis considering CgA levels
from the 129 controls and those from 81 ND patients
with GEP NETs, measured by both IRMA and ELISA
assays.
As shown in Fig. 3A, the cutoff value of 53 ng/ml for
the IRMA assay provided the best compromise
between specificity (71.3%) and sensitivity (77.8%),
and was chosen for further analysis. The area under the
curve (AUC) was 0.834, indicating a good per-
formance of the assay. Using this cutoff, PPV were
54 and 35% and NPV were 92 and 90% for foregut
(esophagus, stomach, pancreas, and duodenum) and
midgut tumors (ileum and colon) respectively.
Analysis of these parameters was then performed
according to the affected organ. Due to the low number
of the GEP NET patients with primary site of the tumor
in the duodenum, colon, and rectum, PPV and NPV
were only calculated for stomach (27 and 99%),
pancreas (43 and 93%), and ileum (29 and 92%)
respectively. CgA levels were below the cutoff value in
96 out of 129 normal individuals (74.4%) and in 28 out
of 45 patients (62%) with endocrine tumors in RM.475
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Table 2 Basal chromogranin A levels in 202 gastroenteropancreatic neuroendocrine tumor patients according to the recruitment
group
New diagnosis Relapse Stable disease Remission
IRMA
(ng/ml) ELISA (U/l)
IRMA
(ng/ml) ELISA (U/l)
IRMA
(ng/ml) ELISA (U/l)
IRMA
(ng/ml) ELISA (U/l)
No. 81 81 27 27 49 49 45 45
Mean 546.1 349.2 624.6 364.4 434.6 160.5 67.3 19.0
S.D. 1496.5 1020.6 872.8 639.7 1441.7 375.5 82.0 14.1
Median 164 67 216 104 57 30 43 15
Range 10–11 720 5–8170 36–3045 7–3018 10–9555 5–2489 10–543 5–66
Percentile
5th 28 9 39 8 19 6 23 6
25th 66 27 69 41 34 15 29 11
50th 164 67 216 104 57 30 43 15
75th 342 215 971 476 132 171 76 24
95th 1410 1423 3040 1551 1745 562 159 53
M C Zatelli et al.: CgA in neuroendocrine tumorsAs shown in Fig. 3B, the cutoff value of 16 U/l for
the ELISA assay provided the best compromise
between specificity (85.3%) and sensitivity (84%),
and was chosen for further analysis. The AUC was
0.892, again indicating a good performance of the
assay. Using this cutoff, PPV were 69 and 57% and
NPV were 93 and 96% for foregut and midgut tumors
respectively. When considering the primary site of the
tumor, PPV and NPV were 42 and 99% for stomach, 60
and 94% for pancreas, and 51 and 97% for ileum
respectively. CgA levels were below this cutoff value
in 110 out of 129 normal individuals (85.3%) and in
25 out of 45 patients (55.6%) with endocrine tumors
in RM.
Considering these cutoff levels, six healthy subjects
having normal CgA levels by IRMA had CgA levels
above the cutoff when assayed by ELISA. On the
contrary, 20 healthy subjects having normal CgA by
ELISA had CgA levels above the cutoff when assayed
by IRMA (discordance rate 20.1%).Figure 1 Comparison between ELISA and IRMA methods in
129 healthy subjects (A) and in 202 GEP NET patients (B).CgA levels in metastatic patients
Among the 202 GEP NET patients, 123 presented with
and 76 without metastases at study entry. Data
concerning the presence or absence of metastases
were missing in three patients. Metastatic patients had
significantly (P!0.0001) higher CgA levels than
patients without metastases, both by IRMA (605.9G
1537.9 ng/ml, range 10–11, 720 ng/ml vs 142.1G
324.6 ng/ml, range 10–2715 ng/ml) and by ELISA
assays (351.5G899.3 U/l, range 5–8170 U/l vs 47.7G
138.9 U/l, range 5–1196 U/l). However, when con-
sidering only the 108 patients with evidence of disease
and without medical treatment at study entry (ND 81
and RL patients 27), the IRMA assay did not476discriminate CgA levels of patients with metastases
from those without (676.1G1554.9 ng/ml, range
10–11, 270 ng/ml vs 272.9G503.6 ng/ml, range
28–2715 ng/ml; PZ0.09). On the other hand, CgAwww.endocrinology-journals.org
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Figure 3 Receiver-operating characteristics curve obtained
with 129 healthy subjects and 81 new diagnosis GEP NET
patients for the IRMA (A) and for the ELISA assays (B).
Figure 2 Comparison between local and central laboratories for
IRMA (A) and ELISA (B) methods in GEP NET patients.
Endocrine-Related Cancer (2007) 14 473–482levels measured by the ELISA assay significantly
differed in the two groups (450.4G1073.2 U/l, range
5–8170 U/l vs 90.2G222.4 U/l, range 6–1196 U/l;
P!0.0002).
In order to identify a CgA cutoff value that could
distinguish between patients with metastases from
those without, we performed a ROC analysis evaluat-
ing CgA levels from affected patients (NDCRLZ
108), excluding patients in RM and those with SD.
Therefore, the ROC curve was constructed by
considering CgA levels measured by both IRMA and
ELISA assays in 79 vs 29 patients with and without
metastases respectively.
As shown in Fig. 4A, with the IRMA assay, the
cutoff value of 146 ng/ml provided the best compro-
mise between specificity (55.6%) and sensitivity
(57.0%), and was chosen for further analysis. The
AUC was 0.613 indicating a modest performance ofwww.endocrinology-journals.orgthe assay. Using this cutoff value, PPV were 49 and
40% and NPV were 72 and 46% for foregut and midgut
tumors respectively. Analysis of these parameters was
then performed according to the affected organ. Due to
the low numerosity, PPV and NPV were only
calculated for stomach (14 and 65%) and pancreas
(84 and 78%) respectively.
As shown in Fig. 4B, with the ELISA assay, the
cutoff value of 67.3 U/l provided the best compromise
between specificity (71.4%) and sensitivity (63.3%),
and was chosen for further analysis. The AUC was
0.727, indicating again a modest performance of the
assay. Using this cutoff value, PPV were 61 and 58%
and NPV were 76 and 65% for foregut and midgut
tumors respectively. When considering the affected
organ, it is worth to underline that for pancreatic NETs,
with the chosen cutoff levels for both IRMA and
ELISA assays, PPV was 84% and NPV was 78%, with
90% specificity and 68% sensitivity. On the other hand,
PPV and NPV for stomach were 22 and 79% with the
ELISA assay.
Table 3 shows CgA levels assessed both by IRMA
and ELISA assays in 79 metastatic GEP NET patients,
belonging to ND and RL groups, according to the477
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Figure 4 Receiver-operating characteristics curve obtained
with 79 patients with metastases and 29 patients without
metastases for the IRMA (A) and for the ELISA assays (B).
M C Zatelli et al.: CgA in neuroendocrine tumorsspread of the disease. Data on disease extension were
missing for nine patients. CgA levels were greater in
patients with liver metastases when compared with
those with locally advanced disease. In addition, CgA
levels, evaluated by both IRMA and ELISA assays,
were lower in patients with extensive metastatic spread
(extra-hepatic metastases; 194.8G123.2 ng/ml, range
69–423 ng/ml; 81.5G70.7 U/l, range 13–255 U/l) than
in those with liver metastases only (800.9G
1206.7 ng/ml, range 36–4690 ng/ml; 515.2G
773.2 U/l, range 9–3018 U/l).Discussion
In this multicenter observational study, we have
focused on assessing the value of CgA as a biochemical
marker for detection of GEP tumors. An important
result of this study is that the employed assays for CgA
measurement, which are the most commonly available
in clinical practice, showed a very good correlation
between them, in agreement with previous reports
(Stridsberg et al. 2003), as well as a good correlation478between the values obtained by the central laboratories
in Venezia and Orbassano and those obtained by the
peripheral laboratories. Therefore, we can assume that
CgA values reported by the laboratories of the 40
Italian centers participating in the study are as reliable
as those obtained in dedicated laboratories and support
the reliability of CgA evaluation in clinical practice.
The results show that CgA levels are highly variable
in our study population, with overlapping levels
between healthy subjects, patients with active disease
(ND, RL, and SD) and patients in RM, as measured by
both IRMA and ELISA assays, suggesting a modest
diagnostic value for CgA assessment in the screening
procedures for GEP NETs.
The limited diagnostic power of CgA measurement
is also underlined by the results of the ROC analysis,
performed by considering healthy subjects and ND
patients. The analysis indeed identified cutoff values
for IRMA and ELISA assays located between the 75th
and the 95th percentile of the CgA values distribution
in healthy controls, with modest sensitivity (77.8 and
84%) and specificity (71.3 and 85.3%) for both IRMA
and ELISA assays respectively. This evidence is in line
with previous reports showing a relatively low
diagnostic value of circulating CgA in NETs (Nobels
et al. 1998, Tomassetti et al. 2001). This may depend
on type, secretory activity, degree of neuroendocrine
differentiation, and total burden of the tumors (Seregni
et al. 2001), as well as on the highly variable CgA
levels of the control group. Indeed, 26 and 16% healthy
subjects had high baseline CgA levels by IRMA and
ELISA assays respectively, probably because of the
many potential tissue sources of the peptide (Lamberts
et al. 2001). Furthermore, chronic atrophic gastritis,
which causes high-circulating CgA levels (Syversen
et al. 2004), was not completely ruled out in our
control group, even if all healthy subjects were
asymptomatic.
The CgA cutoff levels identified by the ROC
analysis in the present study are lower than those
described in previous studies. Stridsberg et al. (2003)
adopted the kit cutoff levels without validating them
and considered a patients group including subjects who
lacked signs of NET. Other authors calculated the
cutoff levels on the basis of control groups lacking
strict exclusion criteria (Ferrari et al. 2004, Nehar et al.
2004) or previously diagnosed with non-GEP NETs
(Ferrari et al. 2004).
The PPV and NPV of CgA measurement for both
IRMA and ELISA were calculated on the basis of the
disease prevalence in our study group. Reliable
epidemiological data concerning GEP NET, essentialwww.endocrinology-journals.org
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Table 3 Basal chromogranin A levels in 79a gastroenteropancreatic neuroendocrine tumor patients according to metastatic spread
Locally advanced disease Liver metastases
Liver and extra-hepatic
metastases
IRMA (ng/ml) ELISA (U/l) IRMA (ng/ml) ELISA (U/l) IRMA (ng/ml) ELISA (U/l)
No. 22 22 39 39 9 9
Mean 359.7 256.8 800.9 515.2 194.8 81.5
S.D. 412.8 449.4 1206.7 773.2 123.2 70.7
Median 199 65 327 219 146 60
Range 22–1410 5–1798 10–4990 8–3300 69–423 13–255
Percentile
5th 27 5 36 9 69 13
25th 44 28 103 95 107 42
50th 199 65 327 219 146 60
75th 491 234 971 562 291 89
95th 1305 1266 4690 3018 423 255
aData on disease extension is missing for nine patients.
Endocrine-Related Cancer (2007) 14 473–482to accurately identify PPV and NPV for CgA levels
prevalence in Italy, are currently lacking. Therefore,
correction for the disease prevalence in the general
population was not performed. As a consequence, data
analysis overestimates PPVs and underestimates
NPVs, probably impairing the diagnostic value of
these parameters. Our analysis shows quite low PPVs,
therefore suggesting even lower PPVs when consider-
ing disease prevalence in the general population. Thus,
the identified PPVs for CgA assessment cannot be
considered reliable discriminators for disease presence.
On the other hand, our analysis shows very high NPVs,
therefore suggesting even higher NPVs when con-
sidering disease prevalence in the general population.
Thus, identified NPVs for CgA assessment could be
considered reliable discriminators for disease absence.
Twenty-eight out of 202 patients (13.9%) were
classified differently by the two assays, suggesting that
CgA assessment with only one out of the two assays is
not sufficient to exclude the presence of increased CgA
levels in these patients. However, the discordance rate
observed in our database is much lower than that
reported by Ferrari et al. (2004). We previously
demonstrated that the discordance between the results
of the two assays is not due to the use of different blood
derivatives (Leon et al. 2005), but might be due to the
different ability of the antibodies to detect CgA-
derived peptides. Moreover, these findings support the
hypothesis that the two CgA kits used may provide
different information, since a 20.1% discordance rate
was also found among healthy subjects.
In keeping with previous studies (Nehar et al. 2004),
we found higher CgA levels in metastatic patients
when compared with those without metastases.www.endocrinology-journals.orgHowever, our study does not demonstrate a statistically
significant difference among patient groups with
increasing metastatic spread as indicated by previous
studies (Nobels et al. 1998, Peracchi et al. 2003). On
the contrary, we found that CgA levels assayed with
both methods were lower in patients with very
extensive metastatic spread when compared with
those having metastases limited to the liver. The
influence of concomitant therapies can be excluded,
since the analysis was performed on newly diagnosed
patients, neither previously treated by surgery nor by
medical therapy. Therefore, the lower CgA levels in
patients with very extensive metastatic spread might be
attributed to a possible loss of neuroendocrine
differentiation, probably indicating a more aggressive
behavior. It has been previously demonstrated that
CgA is normally absent or only focally expressed in
poorly differentiated endocrine carcinomas (Rindi &
Klo¨ppel 2004). However, the lack of complete
information concerning proliferative index and his-
tology in these tumors does not allow us to draw any
definitive conclusion. Follow-up data are needed to
better clarify this issue, also in the light of previous
studies showing that elevated CgA levels are strongly
correlated with tumor volume (Nobels et al. 1997) and
disease extent (Seregni et al. 2001).
The ROC analysis identified a cutoff level of
146 ng/ml for the IRMA and of 67.3 U/l for the
ELISA assays as discriminating between patients with
metastases and those without, but sensitivity (57 and
63.3% respectively) and specificity (55.6 and 71.4%
respectively) were quite low. On the other hand, the
calculated NPVs of CgA measurement for both IRMA
and ELISA assays are very high, suggesting that CgA479
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M C Zatelli et al.: CgA in neuroendocrine tumorsvalues below the identified threshold levels are highly
indicative of the absence of metastases in foregut and
midgut GEP NET patients. Correction for the
prevalence of the disease in the general population
would again result in higher NPVs, suggesting that the
CgA cutoff levels of 146 ng/ml for IRMA and 67.3 U/l
for ELISA could discriminate patients without metas-
tases from metastatic patients. On the other hand, our
analysis showed rather low PPVs for discriminating
metastatic patients, indicating that values above the
chosen cutoff levels are not predictive of the presence
of metastases in the majority of cases, also because
they are very likely overestimates. However, our data
also point out that in patients with pancreatic tumors
CgA levels, evaluated with both methods, have a high
predictive value for the presence of metastases, since
they correctly identify 84% of these patients as having
metastatic disease, with good specificity (90%), but
modest sensitivity (68%). These data suggest that in
patients diagnosed with pancreatic NETs CgA evalu-
ation might be useful to identify patients in which local
anddistantmetastases should be looked for by an accurate
clinical evaluation. This issue is important, since it has
been previously demonstrated that in pancreatic NETs,
the presence of metastases profoundly influences
survival rate, which is significantly better in patients
without metastases (Madeira et al. 1998, Chu et al.
2002, Gullo et al. 2003, Panzuto et al. 2005,
Tomassetti et al. 2005). Moreover, the 5-year survival
rate was reported to be 60–100% for localized disease,
40% for regional disease, 29% for distant metastases,
and 80% for all stages (Eriksson et al. 1990, Modlin
et al. 2003). Therefore, CgA evaluation could have a
clinical value also for prognosis.
The study presented here also found for ELISA a
higher sensitivity and specificity (84 and 85%
respectively) when compared with IRMA assay (71.3
and 77.8% respectively) in identifying patients affected
by NETs. The greater ELISA sensitivity might be due
to a more extensive CgA cleavage by GEP NETs.
Indeed, the IRMA assay mainly evaluates intact
molecules and major CgA fragments, since it employs
two antibodies recognizing the central part of human
CgA, which is unexposed to proteolysis (Degorce et al.
1999, Bernini et al. 2001). In pathological conditions,
such as NETs, different proteolytic processes may take
place, generating a variable number of fragments
(Taupenot et al. 2003), which are better assessed by
the ELISA assay. However, further studies are needed
to address the specific CgA cleavage in different
tumors. Initial proteomic studies have identified 11
novel CgA-derived peptides in endocrine tumors,480supporting the hypothesis that different tumors may
process differently the entire molecule, representing a
possible specific signature (Orr et al. 2002).
In conclusion, our study shows that an accurate
comparison between healthy subjects and GEP NET
patients does not provide cutoff levels that could
discriminate between the two groups with a sensitivity
and a specificity high enough to demonstrate CgA as an
efficient biochemical marker in the diagnostic
screening of GEP NET. These data indicate that CgA
serum levels can be helpful for the clinical manage-
ment of NETs, but with low sensitivity and specificity
for diagnostic purposes. On the other hand, the main
utility of CgA measurement may be in patient
monitoring. Therefore, follow-up prospective data are
necessary to examine the performance of CgA
assessment in evaluating follow-up and treatment
efficacy in GEP NET patients. Further studies are
ongoing to clarify this issue.Acknowledgements
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